Vanda Pharmaceuticals Inc (VNDA)
5.00
-0.10
(-1.96%)
USD |
NASDAQ |
Nov 15, 16:00
5.00
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Research and Development Expense (TTM): 78.93M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 78.93M |
| June 30, 2024 | 78.75M |
| March 31, 2024 | 78.74M |
| December 31, 2023 | 76.82M |
| September 30, 2023 | 70.94M |
| June 30, 2023 | 79.20M |
| March 31, 2023 | 84.04M |
| December 31, 2022 | 85.77M |
| September 30, 2022 | 86.65M |
| June 30, 2022 | 81.44M |
| March 31, 2022 | 80.20M |
| December 31, 2021 | 75.36M |
| September 30, 2021 | 70.88M |
| June 30, 2021 | 63.53M |
| March 31, 2021 | 56.18M |
| December 31, 2020 | 55.58M |
| September 30, 2020 | 53.80M |
| June 30, 2020 | 52.85M |
| March 31, 2020 | 50.90M |
| December 31, 2019 | 48.65M |
| September 30, 2019 | 48.50M |
| June 30, 2019 | 48.54M |
| March 31, 2019 | 47.46M |
| December 31, 2018 | 43.59M |
| September 30, 2018 | 40.83M |
| Date | Value |
|---|---|
| June 30, 2018 | 39.61M |
| March 31, 2018 | 37.40M |
| December 31, 2017 | 38.55M |
| September 30, 2017 | 36.01M |
| June 30, 2017 | 33.12M |
| March 31, 2017 | 32.18M |
| December 31, 2016 | 29.16M |
| September 30, 2016 | 30.29M |
| June 30, 2016 | 32.97M |
| March 31, 2016 | 32.22M |
| December 31, 2015 | 29.14M |
| September 30, 2015 | 25.15M |
| June 30, 2015 | 18.88M |
| March 31, 2015 | 16.44M |
| December 31, 2014 | 19.23M |
| September 30, 2014 | 20.75M |
| June 30, 2014 | 25.07M |
| March 31, 2014 | 27.65M |
| December 31, 2013 | 28.50M |
| September 30, 2013 | 33.17M |
| June 30, 2013 | 35.30M |
| March 31, 2013 | 41.70M |
| December 31, 2012 | 45.76M |
| September 30, 2012 | 45.38M |
| June 30, 2012 | 43.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
48.65M
Minimum
Dec 2019
86.65M
Maximum
Sep 2022
70.46M
Average
76.09M
Median
Research and Development Expense (TTM) Benchmarks
| Zevra Therapeutics Inc | 46.33M |
| Black Diamond Therapeutics Inc | 54.30M |
| Edgewise Therapeutics Inc | 118.28M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |